Symic Biomedical gets $1.5m NIH Phase II SBIR grant to develop proteoglycan mimetic therapeutics
The two-year project, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), will allow Symic to perform additional preclinical efficacy studies and advance lead
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.